304 related articles for article (PubMed ID: 9596295)
1. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team.
Mundy LM; Oldach D; Auwaerter PG; Gaydos CA; Moore RD; Bartlett JG; Quinn TC
Chest; 1998 May; 113(5):1201-6. PubMed ID: 9596295
[TBL] [Abstract][Full Text] [Related]
2. The role of atypical pathogens in community-acquired pneumonia.
Gupta SK; Sarosi GA
Med Clin North Am; 2001 Nov; 85(6):1349-65, vii. PubMed ID: 11680106
[TBL] [Abstract][Full Text] [Related]
3. Importance of atypical pathogens of community-acquired pneumonia.
Plouffe JF
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
[TBL] [Abstract][Full Text] [Related]
4. Empiric treatment of ambulatory community-acquired pneumonia: always include treatment for atypical agents.
Marrie TJ
Infect Dis Clin North Am; 2004 Dec; 18(4):829-41. PubMed ID: 15555827
[TBL] [Abstract][Full Text] [Related]
5. [The role of atypical pathogen: Mycoplasma pneumoniae and Chlamydia pneumoniae in the acute respiratory infection in childhood].
Ouchi K
Jpn J Antibiot; 2000 Jun; 53 Suppl B():13-21. PubMed ID: 12572086
[TBL] [Abstract][Full Text] [Related]
6. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
Piso RJ; Arnold C; Bassetti S
Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
[TBL] [Abstract][Full Text] [Related]
7. Community-acquired pneumonia: role of atypical organisms.
Cosentini R; Tarsia P; Blasi F; Roma E; Allegra L
Monaldi Arch Chest Dis; 2001 Dec; 56(6):527-34. PubMed ID: 11980285
[TBL] [Abstract][Full Text] [Related]
8. First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1-15 years.
Huong Ple T; Hien PT; Lan NT; Binh TQ; Tuan DM; Anh DD
BMC Public Health; 2014 Dec; 14():1304. PubMed ID: 25524126
[TBL] [Abstract][Full Text] [Related]
9. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
10. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
11. Atypical pathogen pneumonia.
Lieberman D; Lieberman D
Curr Opin Pulm Med; 1997 Mar; 3(2):111-5. PubMed ID: 9193855
[TBL] [Abstract][Full Text] [Related]
12. The atypical pneumonias: clinical diagnosis and importance.
Cunha BA
Clin Microbiol Infect; 2006 May; 12 Suppl 3():12-24. PubMed ID: 16669925
[TBL] [Abstract][Full Text] [Related]
13. [Atypical pathogens of pneumonia acquired in ambulant persons].
Tuschy P; Lorenz J
Dtsch Med Wochenschr; 2004 Mar; 129(10):503-8. PubMed ID: 14986239
[No Abstract] [Full Text] [Related]
14. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
[TBL] [Abstract][Full Text] [Related]
15. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
16. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
17. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection.
File TM; Tan JS; Plouffe JF
Infect Dis Clin North Am; 1998 Sep; 12(3):569-92, vii. PubMed ID: 9779379
[TBL] [Abstract][Full Text] [Related]
18. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
[TBL] [Abstract][Full Text] [Related]
19. Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohorts.
Raeven VM; Spoorenberg SM; Boersma WG; van de Garde EM; Cannegieter SC; Voorn GP; Bos WJ; van Steenbergen JE; ;
BMC Infect Dis; 2016 Jun; 16():299. PubMed ID: 27317257
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
